Compare Adaptive Biotechnologies Corp (ADPT) vs Lululemon Athletica Inc (LULU) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs Lululemon Athletica Inc — how do they compare? Adaptive Biotechnologies Corp trades at $20.17 (market cap $3.33B), while Lululemon Athletica Inc trades at $113.39 (market cap $13.13B). The key difference: Lululemon Athletica Inc is far larger — about 3.9× Adaptive Biotechnologies Corp's market cap, and Adaptive Biotechnologies Corp is trading nearer its 52-week high, Lululemon Athletica Inc nearer its low. Which is the better fit depends on your goals.
| ADPT | LULU | |
|---|---|---|
Market Cap | $3.33B | $13.13B |
Sector | Health | Consumer Cyclical |
52-Week High | $22.37 | $238.54 |
52-Week Low | $10.24 | $105.43 |
Enterprise Value | $3.19B | $13.75B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $20.82, down 1.75% today, with a bullish technical signal from moving averages and a consensus analyst price target of $20.40. The company announced a strategic separation of its MRD and Immune Medicine businesses in June 2026, alongside a $300 million convertible notes offering to enhance financial flexibility. Revenue grew to $277 million in 2025, though net losses persist at -$59.50 million, with improving margins and cash flow trends showing net positive cash generation of $22.37 million.
Outlook remains cautiously optimistic as the business split aims to unlock value, but execution risks and sustained profitability challenges pose headwinds. Analysts are predominantly bullish (64.71% buy ratings), citing growth in the clonoSEQ MRD segment, yet the stock faces volatility from high valuation multiples and insider selling activity.
LULU trades at $115.07, down 2.84% for the day, reflecting recent bearish sentiment amid a 45% year-to-date decline. The stock is near its pivot point of $115, with technical indicators signaling a bearish trend. Fundamentally, the company reported strong revenue of $10.59B in 2025 and a net income margin of 17.13%, with a low P/E of 9.36 suggesting undervaluation. Recent news highlights board settlement with founder Chip Wilson but also cultural missteps in China and a class-action lawsuit over tariff costs.
The outlook is mixed: attractive valuation and international growth potential contrast with North American weakness and brand reputation risks. Analyst consensus is a $130.53 price target with 41% buy ratings, but near-term volatility persists. Key risks include execution on guidance, competitive pressures, and macroeconomic headwinds affecting consumer spending.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About Lululemon Athletica Inc
Lululemon Athletica Inc. designs, distributes, and markets athletic apparel, footwear, and accessories for women, men, and girls. Lululemon offers pants, shorts, tops, and jackets for both leisure and athletic activities such as yoga and running. The company also sells fitness accessories, such as bags, yoga mats, and equipment. Lululemon sells its products through more than 600 company-owned stores in 18 countries, e-commerce, outlets, and wholesale accounts. The company was founded in 1998 and is based in Vancouver, Canada.
Read more on LULU →
